MarketCap
Facebook
X
TelegramAnnual report 2022
added 08-16-2022
Happiness Biotech Group Limited Total Non Current Liabilities 2011-2026 | HAPP
Annual Total Non Current Liabilities Happiness Biotech Group Limited
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | - | 209 K | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 209 K | 209 K | 209 K |
Total Non Current Liabilities of other stocks in the Biotechnology industry
| Issuer | Total Non Current Liabilities | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
FSD Pharma
HUGE
|
79.1 K | - | 5743.5 % | $ 69.7 M |  Canada |
 |
MorphoSys AG
MOR
|
40.2 M | - | 2.43 % | $ 254 M |  Germany |
 |
AgeX Therapeutics
AGE
|
1.53 M | - | -10.17 % | $ 12.2 K |  USA |
 |
I-Mab
IMAB
|
131 M | - | - | $ 866 M |  China |
 |
Midatech Pharma plc
MTP
|
110 K | - | -18.52 % | $ 27.3 M |  Britain |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
4.83 B | - | - | $ 40.3 B | USA |
 |
Biophytis SA
BPTS
|
2.02 M | - | -13.47 % | $ 169 M |  France |
 |
Genfit SA
GNFT
|
184 M | - | 2.54 % | $ 160 B | France |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
6.39 M | - | -1.52 % | $ 24.7 M | USA |
 |
Athira Pharma
ATHA
|
876 K | - | - | $ 269 M | USA |
 |
BiondVax Pharmaceuticals Ltd.
BVXV
|
7.32 M | - | 0.74 % | $ 768 M |  Israel |
 |
AbbVie
ABBV
|
81.7 B | $ 201.55 | - | $ 357 B | USA |
 |
Anika Therapeutics
ANIK
|
26.1 M | $ 14.77 | - | $ 216 M | USA |
 |
Autolus Therapeutics plc
AUTL
|
50.6 M | $ 1.57 | - | $ 418 M | Britain |
 |
BioNTech SE
BNTX
|
622 M | $ 94.13 | - | $ 22.8 B | Germany |
 |
Институт стволовых клеток человека
ISKJ
|
541 M | - | - | - |  Russia |
 |
Compugen Ltd.
CGEN
|
31.3 M | $ 2.9 | - | $ 271 M | Israel |
 |
Enlivex Therapeutics Ltd.
ENLV
|
383 M | $ 0.77 | - | $ 35.2 M | Israel |
 |
ACADIA Pharmaceuticals
ACAD
|
49.6 M | $ 22.4 | - | $ 3.71 B | USA |
 |
Esperion Therapeutics
ESPR
|
355 M | $ 3.14 | - | $ 653 M | USA |
 |
Exelixis
EXEL
|
63.6 M | $ 48.16 | - | $ 13.1 B | USA |
 |
Genmab A/S
GMAB
|
769 M | $ 26.43 | - | $ 1.71 B |  Danmark |
 |
Fortress Biotech
FBIO
|
83.9 M | $ 2.39 | - | $ 66.7 M | USA |
|
Forte Biosciences
FBRX
|
10.5 M | $ 24.02 | - | $ 311 M | USA |
 |
Advaxis
ADXS
|
16 M | - | -9.65 % | $ 45.9 M | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
1.19 M | $ 3.51 | -0.57 % | $ 5.78 M | Israel |
 |
Aeterna Zentaris
AEZS
|
14 M | - | 5.93 % | $ 314 M | Canada |
 |
Gilead Sciences
GILD
|
29.2 B | $ 131.33 | - | $ 163 B | USA |
 |
Aeglea BioTherapeutics
AGLE
|
4.74 M | - | - | $ 1.01 B | USA |
 |
CureVac N.V.
CVAC
|
112 M | - | - | $ 867 M | Germany |
 |
Applied Genetic Technologies Corporation
AGTC
|
4.15 M | - | - | $ 26.5 M | USA |
 |
AIkido Pharma
AIKI
|
2.29 M | - | 1.93 % | $ 17.4 M | USA |
 |
Grifols, S.A.
GRFS
|
10.6 B | $ 8.1 | - | $ 5.51 B |  Spain |
 |
Akero Therapeutics
AKRO
|
1.52 M | - | - | $ 3.67 B | USA |
 |
Aptose Biosciences
APTO
|
27.9 M | - | -45.71 % | $ 1.2 M | Canada |
 |
Aptinyx
APTX
|
114 K | - | -39.0 % | $ 4.57 M | USA |
 |
Akouos
AKUS
|
12 M | - | 0.23 % | $ 488 M | USA |
 |
Albireo Pharma
ALBO
|
79.1 M | - | -0.23 % | $ 916 M | USA |
 |
Allakos
ALLK
|
8.11 M | - | - | $ 28.6 M | USA |
 |
AlloVir
ALVR
|
5.46 M | - | 4.14 % | $ 49.1 M | USA |
 |
Arcutis Biotherapeutics
ARQT
|
167 M | $ 21.17 | - | $ 2.69 B | USA |
 |
Allena Pharmaceuticals
ALNA
|
10.2 M | - | 3.16 % | $ 1.9 M | USA |
 |
Ampio Pharmaceuticals
AMPE
|
3.53 M | - | -11.43 % | $ 502 K | USA |
|
Applied Molecular Transport
AMTI
|
106 M | - | - | $ 10.1 M | USA |
 |
Jazz Pharmaceuticals plc
JAZZ
|
2.06 B | $ 225.79 | - | $ 13.8 B |  Irlanda |
 |
Alpine Immune Sciences
ALPN
|
15.9 M | - | - | $ 2.17 B | USA |
 |
Aileron Therapeutics
ALRN
|
4.59 M | - | 10.36 % | $ 9.8 M | USA |
 |
Applied Therapeutics
APLT
|
797 K | - | - | $ 8.42 M | USA |